On the Record · Integra Lifesciences Holdings

Integra Lifesciences Holdings acquisitions, on the record

The businesses Integra Lifesciences Holdings bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Acclarent, Inc. Word for word“In December 2023, we entered into a definitive agreement to acquire Acclarent from Johnson & Johnson, for $275.0 million in cash, subject to customary purchase price adjustments, and a cash payment of $5.0 million upon the achievement of a regulatory milestone.” 10-K for 2023	agreed acquisition	December 2023	$275.0 million in cash
Surgical Innovation Associates, Inc. Word for word“On December 6, 2022, we completed its acquisition of SIA for an acquisition purchase price of $51.5 million.” 10-K for 2023	acquisition	December 6, 2022	$51.5 million
ACell, Inc. Word for word“Between January 1, 2021 and December 31, 2023, we have acquired two businesses at a total cost of approximately $358.4 million which amount includes our acquisition of ACell, Inc. in January 2021 for $306.9 million and our acquisition of Surgical Innovation Associates, Inc. for $51.5 million in December 2022.” 10-K for 2023	acquisition	January 2021	$306.9 million
TWC business Word for word“On August 31, 2022, the Company completed the sale of its TWC business to Gentell, Inc. (“Gentell”) for $28.8 million, which consists of $27.8 million in cash plus $1.0 million in contingent consideration which may be received upon achieving certain revenue-based performance milestones two years after the closing date.” 10-K for 2023	divestiture	August 31, 2022	$28.8 million
Durepair Regeneration Matrix product rights Word for word“On October 2, 2024, the Company completed the acquisition of the product rights for Durepair ® Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures manufactured in our Boston facility and sold under a private label arrangement, from Medtronic plc for total cash consideration of $45.0 million.” 10-K for 2024	acquisition	On October 2, 2024	$45.0 million
non-core traditional wound care (TWC) business Word for word“On August 31, 2022, the Company completed the sale of its non-core traditional wound care (“TWC”) business to Gentell, Inc. (“Gentell”) for $28.8 million, which consists of $27.8 million in cash plus $1.0 million in contingent consideration which may be received upon achieving certain revenue-based performance milestones two years after the closing date.” 10-K for 2024	divestiture	On August 31, 2022	$28.8 million
Durepair® Regeneration Matrix product rights (from Medtronic plc) Word for word“On October 2, 2024, the Company completed the acquisition of the product rights for the Durepair ® Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total cash consideration of $45.0 million.” 10-K for 2025	acquisition	On October 2, 2024	total cash consideration of $45.0 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)	Cash received from selling businesses	Goodwill from acquisitions
2016-12-31	−$225,000	$0	—
2017-12-31	$1.24 billion	$46.4 million	—
2018-12-31	−$26.7 million	$0	—
2019-12-31	$30.5 million	$0	—
2020-12-31	—	$0	—
2021-12-31	—	$190.5 million	$94.1 million
2022-12-31	—	$24 million	—
2023-12-31	—	$0	—
2024-12-31	—	$0	—

Deal filings since 2016

2026-10-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-04-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-06-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-12-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-12-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-03-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-12-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-12-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-09-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-07-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-02-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-02-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-12-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-05-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-05-09 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-12-18 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-10-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-09-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-05-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-02-24 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-02-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-01-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-12-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-10-28 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets

Read from Integra Lifesciences Holdings’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.